Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Atopic Dermatitis

Free Access

Atopic Dermatitis: Global Epidemiology and Risk Factors

Nutten S.

Author affiliations

Nutrition and Health Department, Nestlé Research Center, Lausanne, Switzerland

Corresponding Author

Sophie Nutten, PhD

Nutrition and Health Department

Nestlé Research Center

PO Box 44, CH-1000 Lausanne 26 (Switzerland)

E-Mail sophie.nutten@rdls.nestle.com

Related Articles for ""

Ann Nutr Metab 2015;66(suppl 1):8-16

Abstract

Atopic dermatitis (AD) is a chronic inflammatory skin disease posing a significant burden on health-care resources and patients' quality of life. It is a complex disease with a wide spectrum of clinical presentations and combinations of symptoms. AD affects up to 20% of children and up to 3% of adults; recent data show that its prevalence is still increasing, especially in low-income countries. First manifestations of AD usually appear early in life and often precede other allergic diseases such as asthma or allergic rhinitis. Individuals affected by AD usually have genetically determined risk factors affecting the skin barrier function or the immune system. However, genetic mutations alone might not be enough to cause clinical manifestations of AD, and it is merely the interaction of a dysfunctional epidermal barrier in genetically predisposed individuals with harmful effects of environmental agents which leads to the development of the disease. AD has been described as an allergic skin disease, but today, the contribution of allergic reactions to the initiation of AD is challenged, and it is proposed that allergy is rather a consequence of AD in subjects with a concomitant underlying atopic constitution. Treatment at best achieves symptom control rather than cure; there is thus a strong need to identify alternatives for disease prevention.

© 2015 S. Karger AG, Basel


Key Messages

• Atopic dermatitis (AD) is a common inflammatory skin disease posing a significant burden on health-care resources and patients' quality of life.

• AD usually starts in early childhood and can be the initial step of the so-called ‘atopic march'.

• The prevalence of AD is as high as 20% in children in some countries and continues to increase, affecting now not only developed countries but also low-income countries.

• AD is a complex disease, and the relationship between allergy and AD (allergy being a cause and/or an exacerbating factor of AD) is still debated.

• Genetics has recently been shown to be an important risk factor for AD, and the strongest association so far with the gene encoding filaggrin has raised the recent interest in the role of skin barrier impairment in the development of AD.

• Environmental factors and specifically exposure to microbes are also recognized to play a role in the development of the disease.

• AD is a multifactorial disease presenting with different endophenotypes.

• The prevention of AD should start as soon as possible (possibly even in utero), targeting both skin barrier, immune/allergy and environmental aspects.

Introduction

Atopic dermatitis (AD), also called atopic eczema, is a common chronic or recurrent inflammatory skin disease and affects 15-20% of children [1] and 1-3% of adults worldwide. It is characterized by acute flare-ups of eczematous pruritic lesions over dry skin.

AD usually starts in early childhood and may represent the initial step of the so-called ‘atopic march' (fig. 1) which represents the natural history of atopic manifestations, characterized by a typical sequence of atopic diseases in childhood preceding the development of other allergic disorders later in life [2,3,4]. Fifty percent of all those with AD develop other allergic symptoms within their first year of life and probably as many as 85% of the patients experience an onset below 5 years of age. Patients usually outgrow the disease in late childhood as around 70% of the patients with a disease onset during childhood have a spontaneous remission before adolescence. However, early childhood AD is often the initial indication that a child may later develop asthma and/or allergic rhinitis (hay fever) [5].

Fig. 1

Incidence of different types of atopy by age: AD is considered as the first manifestation of the atopic march. Reproduced from Barnetson and Rogers [2] with permission from the BMJ Publishing Group Ltd.

http://www.karger.com/WebMaterial/ShowPic/130962

Symptoms of AD include patches of skin that are red or brownish, dry, cracked or scaly skin and itchy skin, especially at night. In infants, eczema usually appears as tiny bumps on the cheeks, while older children and adults often experience rashes on the knees or elbows (often in the folds of the joints), on the backs of the hands or on the scalp.

AD poses a significant burden on health-care resources [6,7,8] and patients' quality of life (mainly because of sleep deprivation due to itchiness, employment loss, time to care and financial costs) [9,10,11,12]. As a consequence, there has been a heightened interest in the identification of environmental risks and protective factors.

Epidemiology

The prevalence of AD is estimated to be 15-20% in children and 1-3% in adults, and the incidence has in-creased by 2- to 3-fold during the past decades in industrialized countries.

Some of the most valuable AD prevalence and trend data have come from the International Study of Asthma and Allergies in Childhood (ISAAC). This is the biggest (close to 2 million children in 100 countries) and only allergy study that has taken a truly global approach. The strength of the study is the use of a uniformly validated methodology allowing a direct comparison of results between pediatric populations all over the world (http://isaac.auckland.ac.nz/index.html).

The study revealed that over 20% of children are affected by AD in some countries, but that the prevalence varies greatly throughout the world. For the age group 6-7 years, data showed that the prevalence of AD ranged from 0.9% in India to 22.5% in Ecuador, with new data showing high values in Asia and Latin America. For the age group 13-14 years, data showed prevalence values ranging from 0.2% in China to 24.6% in Columbia. A prevalence over 15% was found in 4 of 9 regions studied including Africa, Latin America, Europe (1 center in Finland) and Oceania [13].

Importantly, the latest available data (Phase Three of the ISAAC study) [14] showed that while AD seems to have reached a plateau in the countries with the highest prevalence such as the UK and New Zealand, AD continues to increase in prevalence, specifically in young children (age 6-7 as compared to age 13-14 years) and in low-income countries, such as Latin America or South East Asia which have emerged as regions of a relatively high prevalence in the follow-up data [15] (fig. 2).

Fig. 2

World maps showing changes in the prevalence of AD symptoms for 13- to 14-year-olds (a) and 6- to 7-year-olds (b) in consecutive prevalence surveys conducted 5-10 years apart (between ISAAC Phases One and Three). SE = Standard error of the change. Reproduced from Williams et al. [15] with permission from Elsevier.

http://www.karger.com/WebMaterial/ShowPic/130961

Immune Mechanisms

The immune response observed during the course of AD is characterized by a biphasic inflammation. A Th2-biased immune response (IL-4, IL-13, TSLP and eosinophils) is predominant in the initial and acute phase of AD, while in chronic AD skin lesions, a Th1/Th0 dominance has been described (IFN-γ, IL-12, IL-5 and GM-CSF) [16].

In addition, regulatory T cells and the innate immune system in the skin are altered [17]. The innate immune system represents the first line of defense against infections. In AD, a decrease in the antimicrobial peptides (one component of the skin innate immune system) has been observed and may explain the susceptibility to infections in AD patients [18]. Specifically, lesional and healthy skin of AD patients is frequently colonized with Staphylococcus aureus which exacerbates or aggravates skin lesions [19].

Allergy and AD

Presence of food sensitization and allergy earlier in life predicts a prognosis of severe AD. Around 50-70% of children with an early onset of AD are sensitized to one or more allergens. These are mainly food allergens (cow's milk, hen's egg and peanuts being the foods most frequently involved) [20] but also house dust mite, pollen and pets. Food allergy is actually much more common in children with AD with an association that ranges from 20 to 80% but is more accepted around 30%.

The relationship between food allergy and AD is complex and can be viewed from different perspectives. It has been proposed recently that food allergy may not have such an important impact on the initiation of AD. In most cases, rather than being a cause of AD (‘inside-out hypothesis': the skin lesions of AD are a consequence of the inflammatory response to allergens), food allergy would be co-associated with AD or would be an exacerbating factor for AD [21]. Food allergies have indeed clinical manifestations on the skin and in the gastrointestinal and respiratory systems. Cutaneous reactions can be diverse, but only some of them will exacerbate AD, and they usually manifest as a late event. Skin reactions can anyway lead to excessive scratching and indirect exacerbation of preexisting eczema.

Genetic Factors

The role of genetics as an important risk factor for AD has first been found in observation studies, describing a positive parental history in AD patients, and in twin studies, showing a higher concordance rate in monozygotic twins compared to dizygotic twins [22]. Then, genetic linkage analysis as well as association studies identified several genes linked to either epidermal function or the immune system.

The recent discovery of the common loss-of-function variants in the FLG gene (encoding the epidermal barrier protein filaggrin) and their strong association with AD [23] has led to a heightened interest in the role of skin barrier impairment in the development of AD, allergic sensitization and also food and respiratory allergies. Filaggrin has a crucial role in skin barrier integrity. It is an important epidermal protein that is needed for the formation of the corneocytes as well as the generation of intracellular metabolites which contribute to stratum corneum hydration and pH of the skin. Ten percent of the westernized population and 50% of AD patients carry mutations in the FLG gene, and 20 mutations in the FLG gene have been described so far.

Other skin-related genes such as SPINK5/LEKT1 have also been identified as being associated with AD [24,25], and, in addition, different tissue-specific patterns of DNA methylation have been identified as first evidence for the relevance of epigenetic modifications in AD.

Altogether, these data have raised the recent interest in the role of skin barrier impairment in the development of AD and allergic sensitization [26,27].

Impaired Skin Barrier Function

An intact epidermal barrier is a prerequisite for the skin to function as a physical and chemical barrier. Genetically determined alterations of the epidermis or lipid composition contribute to skin barrier dysfunction leading to inflammation. Moreover, the defective epidermal barrier allows easier and enhanced environmental allergen penetration through the skin, facilitating the interaction of the allergens with the local antigen-presenting cells and immune effector cells. This may lead to systemic IgE sensitization and transition from the nonatopic state to the atopic state of the disease (fig. 3). This is called the ‘outside-in hypothesis', explaining the association between AD and an increased risk of developing food allergy, asthma and allergic rhinitis (atopic march). Allergic sensitization would be mainly a secondary phenomenon in AD and an important trigger of disease flares and driver of disease chronicity. Patients carrying variations for filaggrin and other genes and suffering from an early onset and rather severe form of AD have the highest risk to develop allergic diseases and specifically asthma.

Fig. 3

Genes and the environment in the natural history of AD. Consequently to a genetically determined skin barrier dysfunction and the aggravating effect of environmental factors, nonatopic dermatitis is the first and most prevalent manifestation of AD early in life. In parallel, an atopic predisposition is involved in the sensitization to allergens, leading to the IgE-associated form of AD. Scratching, bacterial infections or other environmental factors such as soap act as aggravating factors due to their damaging effect on the skin barrier.

http://www.karger.com/WebMaterial/ShowPic/130960

The skin barrier defect in AD also predisposes to colonization or infection by pathogenic microbes (e.g. S. aureus) whose exogenous proteases can also further damage the skin barrier.

Causes of this abnormal skin barrier are complex and driven by a combination of genetic and immunological factors (see above) but also environmental factors (fig. 3). Typically, addition of environmental interactions such as washing with soap and detergents can further impair the barrier function.

Environmental Factors and Microbial Exposure

Significant variations in the prevalence between and within countries (e.g. urban-rural gradient of disease) suggest environmental factors in addition to genetic factors as the main drivers of change in disease burden. Environmental risk factors such as climate, urban versus rural setting, diet, breastfeeding and time of weaning, obesity and physical exercise or tobacco smoke and pollution have been proposed (table 1).

Table 1

Environmental risk factors for AD (nonexhaustive list)

http://www.karger.com/WebMaterial/ShowPic/130964

Also, studies have suggested that microbial exposure could influence the development of AD (table 2) [28]. The ‘revised' hygiene hypothesis states that the decrease in early childhood exposure to prototypical infections (e.g. hepatitis and tuberculosis) and, by extension, in any microbial exposure [29] has increased the susceptibility to allergic disease. For AD, this hypothesis has been supported by some observations such as that the youngest among siblings has the lowest risk of AD or that AD risk is decreased in infants attending day care during their first year of life. The influence of a farm environment (and exposure to a variety of microfloras) has also been extensively studied within cohorts [30,31,32,33,34,35]. The results showed that rather than living on a farm, it is the consumption of unpasteurized farm milk during the first 2 years of life and the direct contact of pregnant mothers with farm animals which appeared to be protective [32,35].

Table 2

Individual factors linked to microbial exposure (nonexhaustive list)

http://www.karger.com/WebMaterial/ShowPic/130963

Studies on pets also proposed dog exposure as a protective factor [36], while for cat exposure, the situation is less clear with much more heterogeneous results [37]. The risk of developing AD is increased in infants who have been exposed to a cat during their first year of life only if they carry filaggrin mutations. This example underlines the complex interplay between genetics and the environment.

Antibiotics (rather than the infection itself which is treated with the antibiotics) seemed to be linked to an increased risk of AD [38,39]. The explanation may be linked to the microbiota changes related to antibiotic use, knowing that the microbiota influences the immune response. There is actually evidence showing that the early gut microbiota of children who develop AD later in life is different from that of children who do not develop AD, both in terms of composition [40,41,42,43] and diversity [44]. More recently, the skin microbiota has been suggested to be involved in the homeostasis of the immune system of the skin and may also have an impact on AD [45].

Prevention of AD

Taking into account the burden on health-care resources, the impact on the quality of life of patients and their caregivers, together with increasing evidence that AD may progress to other allergic phenotypes, there is a clear need to improve disease prevention [46]. The still growing understanding of the pathoetiology and of environmental risk factors for AD contributes to this goal [47].

Due to the childhood prevalence of the disease, prevention is focused on the perinatal period. It is recognized that prevention should start as soon as possible (even possibly in utero), targeting the skin barrier, immune/allergy and environmental aspects.

Infant Feeding

Breastfeeding is a protective factor even though little evidence shows that exclusive breastfeeding beyond 3 months of age is protective [48]. While food avoidance was proposed earlier, the results of recent observational studies have shown that delaying the introduction of solids is a risk factor for AD [49,50,51,52,53], and today, methods favoring tolerance induction are used. For infants who cannot be breastfed, infant formulas have been developed. Specifically, partially hydrolyzed or extensively hydrolyzed formulas are proposed to fit infants at risk of allergy and infants already having symptoms of cow's milk allergy. Intervention studies have shown that prolonged feeding with a partially hydrolyzed whey formula, compared to a cow's milk formula, may result in an around 45% reduction in infantile AD in at-risk infants [54,55]. The German Infant Nutritional Intervention (GINI) study even reported a significant risk reduction in AD up to 10 years of age for infants who received a whey-based partially hydrolyzed formula and those who received an extensively hydrolyzed casein formula [56,57,58]. One of the plausible mechanisms behind this observation is that a low exposure to protein or peptides (such as hydrolyzed proteins) could educate the immune system to develop tolerance.

Modulating the Gut Flora

Pre- and probiotics have also been used during the prenatal and/or postnatal period in an attempt to modify the gut microbiota towards more diversity and a ‘healthier' composition. Different probiotics (mainly Lactobacilli and Bifidobacteria), used individually or in combination and administered at different periods (prenatally and/or postnatally), have been used in clinical trials. A recent meta-analysis associated the consumption of probiotics during pregnancy and early life with a relative risk reduction for AD of 21% [59]. Encouraging results have also been obtained with prebiotics (substrates inducing growth and activity of probiotics). A Cochrane review and a meta-analysis recently showed that using prebiotics in the postnatal period could reduce AD by 30% at 2 years of age [60]. However, due to heterogeneity in studies, further research is still needed before pre- and/or probiotics can be routinely recommended as an effective means to prevent AD [61].

Dietary Supplementation

Dietary supplementation (vitamins, zinc, selenium, oils, etc.) has also been tested prenatally or postnatally [62]. Due to its immune-modulatory effect, vitamin D has been studied in the AD prevention context; however, results are still conflicting. Numerous studies also suggested that a high consumption of fish during pregnancy decreased the risk of developing AD in the infant [63]. Similar results were obtained when fish was consumed during late infancy [64,65].

Preventing a Skin Barrier Breakdown

Due to its major role in AD initiation, protecting the skin barrier should be a powerful measure for prevention, especially in children who carry skin barrier gene mutations and show early signs of skin barrier impairment. Moreover, the skin barrier may constitute a target of primary prevention of progression of eczema into allergic airway diseases. Encouraging results have been obtained with the application of emollients, combined with soap avoidance, and a large-scale randomized clinical trial is underway (Barrier Enhancement for Eczema Prevention study; http://www.beepstudy.org).

Conclusion

AD is a multifactorial, chronic inflammatory and heterogeneous skin disorder resulting from interactions between genetic, immune and environmental factors. It is common in most countries, although the prevalence varies greatly throughout the world. Recent data revealed that AD is a disease of developed as well as developing countries, and in poorer countries, AD will be competing for meager resources. AD has become a significant public health problem because of its presence in most countries and its increasing prevalence, together with increasing evidence that it may progress to other allergic phenotypes. The last few years have seen important improvement in the understanding of the interactions between the skin barrier, genetic and immunological factors. A better understanding of the key environmental risk factors that could be influenced, changed or modified is important for a better prevention of the disease.

Disclosure Statement

The author declares no conflicts of interest.


References

  1. Asher MI, Montefort S, Bjorksten B, Lai CK, Strachan DP, Weiland SK, Williams H: Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. Lancet 2006;368:733-743.
  2. Barnetson RS, Rogers M: Childhood atopic eczema. BMJ 2002;324:1376-1379.
  3. Dharmage SC, Lowe AJ, Matheson MC, Burgess JA, Allen KJ, Abramson MJ: Atopic dermatitis and the atopic march revisited. Allergy 2014;69:17-27.
  4. Shaker M: New insights into the allergic march. Curr Opin Pediatr 2014;26:516-520.
  5. Spergel JM: From atopic dermatitis to asthma: the atopic march. Ann Allergy Asthma Immunol 2010;105:99-106.
  6. Kemp AS: Cost of illness of atopic dermatitis in children: a societal perspective. Pharmacoeconomics 2003;21:105-113.
  7. Mancini AJ, Kaulback K, Chamlin SL: The socioeconomic impact of atopic dermatitis in the United States: a systematic review. Pediatr Dermatol 2008;25:1-6.
  8. Verboom P, Hakkaart-Van L, Sturkenboom M, De Zeeuw R, Menke H, Rutten F: The cost of atopic dermatitis in the Netherlands: an international comparison. Br J Dermatol 2002;147:716-724.
  9. Arnold RJ, Donnelly A, Altieri L, Wong KS, Sung J: Assessment of outcomes and parental effect on quality-of-life endpoints in the management of atopic dermatitis. Manag Care Interface 2007;20:18-23.
    External Resources
  10. Carroll CL, Balkrishnan R, Feldman SR, Fleischer AB Jr, Manuel JC: The burden of atopic dermatitis: impact on the patient, family, and society. Pediatr Dermatol 2005;22:192-199.
  11. Lewis-Jones S: Quality of life and childhood atopic dermatitis: the misery of living with childhood eczema. Int J Clin Pract 2006;60:984-992.
  12. Weisshaar E, Diepgen TL, Bruckner T, Fartasch M, Kupfer J, Lob-Corzilius T, Ring J, Scheewe S, Scheidt R, Schmid-Ott G, Schnopp C, Staab D, Szcepanski R, Werfel T, Wittenmeier M, Wahn U, Gieler U: Itch intensity evaluated in the German Atopic Dermatitis Intervention Study (GADIS): correlations with quality of life, coping behaviour and SCORAD severity in 823 children. Acta Derm Venereol 2008;88:234-239.
    External Resources
  13. Odhiambo JA, Williams HC, Clayton TO, Robertson CF, Asher MI: Global variations in prevalence of eczema symptoms in children from ISAAC Phase Three. J Allergy Clin Immunol 2009;124:1251-1258.
  14. Mallol J, Crane J, von Mutius E, Odhiambo J, Keil U, Stewart A; ISAAC Phase Three Study Group: The International Study of Asthma and Allergies in Childhood (ISAAC) Phase Three: a global synthesis. Allergol Immunopathol (Madr) 2013;41:73-85.
  15. Williams H, Stewart A, von Mutius E, Cookson W, Anderson HR; International Study of Asthma and Allergies in Childhood (ISAAC) Phase One and Three Study Groups: Is eczema really on the increase worldwide? J Allergy Clin Immunol 2008;121:947-954.
  16. Fiset PO, Leung DY, Hamid Q: Immunopathology of atopic dermatitis. J Allergy Clin Immunol 2006;118:287-290.
  17. McGirt LY, Beck LA: Innate immune defects in atopic dermatitis. J Allergy Clin Immunol 2006;118:202-208.
  18. Ong PY, Ohtake T, Brandt C, Strickland I, Boguniewicz M, Ganz T, Gallo RL, Leung DY: Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med 2002;347:1151-1160.
  19. Cardona ID, Cho SH, Leung DY: Role of bacterial superantigens in atopic dermatitis: implications for future therapeutic strategies. Am J Clin Dermatol 2006;7:273-279.
  20. Eigenmann PA, Sicherer SH, Borkowski TA, Cohen BA, Sampson HA: Prevalence of IgE-mediated food allergy among children with atopic dermatitis. Pediatrics 1998;101:E8.
  21. Suh KY: Food allergy and atopic dermatitis: separating fact from fiction. Semin Cutan Med Surg 2010;29:72-78.
    External Resources
  22. Schultz Larsen FV, Holm NV: Atopic dermatitis in a population based twin series. Concordance rates and heritability estimation. Acta Derm Venereol Suppl (Stockh) 1985;114:159.
    External Resources
  23. Palmer CN, Irvine AD, Terron-Kwiatkowski A, Zhao Y, Liao H, Lee SP, Goudie DR, Sandilands A, Campbell LE, Smith FJ, O'Regan GM, Watson RM, Cecil JE, Bale SJ, Compton JG, DiGiovanna JJ, Fleckman P, Lewis-Jones S, Arseculeratne G, Sergeant A, Munro CS, El Houate B, McElreavey K, Halkjaer LB, Bisgaard H, Mukhopadhyay S, McLean WH: Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet 2006;38:441-446.
  24. Barnes KC: An update on the genetics of atopic dermatitis: scratching the surface in 2009. J Allergy Clin Immunol 2010;125:16-29.
  25. Moffatt MF: SPINK5: a gene for atopic dermatitis and asthma. Clin Exp Allergy 2004;34:325-327.
  26. Cork MJ, Robinson DA, Vasilopoulos Y, Ferguson A, Moustafa M, MacGowan A, Duff GW, Ward SJ, Tazi-Ahnini R: New perspectives on epidermal barrier dysfunction in atopic dermatitis: gene-environment interactions. J Allergy Clin Immunol 2006;118:3-21.
  27. Brown SJ, Asai Y, Cordell HJ, Campbell LE, Zhao Y, Liao H, Northstone K, Henderson J, Alizadehfar R, Ben-Shoshan M, Morgan K, Roberts G, Masthoff LJ, Pasmans SG, van den Akker PC, Wijmenga C, Hourihane JO, Palmer CN, Lack G, Clarke A, Hull PR, Irvine AD, McLean WH: Loss-of-function variants in the filaggrin gene are a significant risk factor for peanut allergy. J Allergy Clin Immunol 2011;127:661-667.
  28. Flohr C, Pascoe D, Williams HC: Atopic dermatitis and the ‘hygiene hypothesis': too clean to be true? Br J Dermatol 2005;152:202-216.
  29. Flohr C, Yeo L: Atopic dermatitis and the hygiene hypothesis revisited. Curr Probl Dermatol 2011;41:1-34.
  30. Braback L, Hjern A, Rasmussen F: Trends in asthma, allergic rhinitis and eczema among Swedish conscripts from farming and non-farming environments. A nationwide study over three decades. Clin Exp Allergy 2004;34:38-43.
  31. Braun-Fahrländer C, Gassner M, Grize L, Neu U, Sennhauser FH, Varonier HS, Vuille JC, Wüthrich B: Prevalence of hay fever and allergic sensitization in farmer's children and their peers living in the same rural community. SCARPOL team. Swiss Study on Childhood Allergy and Respiratory Symptoms with Respect to Air Pollution. Clin Exp Allergy 1999;29:28-34.
  32. Douwes J, Cheng S, Travier N, Cohet C, Niesink A, McKenzie J, Cunningham C, Le Gros G, von Mutius E, Pearce N: Farm exposure in utero may protect against asthma, hay fever and eczema. Eur Respir J 2008;32:603-611.
  33. Kilpelainen M, Terho EO, Helenius H, Koskenvuo M: Farm environment in childhood prevents the development of allergies. Clin Exp Allergy 2000;30:201-208.
  34. Riedler J, Eder W, Oberfeld G, Schreuer M: Austrian children living on a farm have less hay fever, asthma and allergic sensitization. Clin Exp Allergy 2000;30:194-200.
  35. von Mutius E: Maternal farm exposure/ingestion of unpasteurized cow's milk and allergic disease. Curr Opin Gastroenterol 2012;28:570-576.
  36. Langan SM, Flohr C, Williams HC: The role of furry pets in eczema: a systematic review. Arch Dermatol 2007;143:1570-1577.
  37. Pelucchi C, Galeone C, Bach JF, La Vecchia C, Chatenoud L: Pet exposure and risk of atopic dermatitis at the pediatric age: a meta-analysis of birth cohort studies. J Allergy Clin Immunol 2013;132:616-622.
  38. Dom S, Droste JH, Sariachvili MA, Hagendorens MM, Oostveen E, Bridts CH, Stevens WJ, Wieringa MH, Weyler JJ: Pre- and post-natal exposure to antibiotics and the development of eczema, recurrent wheezing and atopic sensitization in children up to the age of 4 years. Clin Exp Allergy 2010;40:1378-1387.
  39. Tsakok T, McKeever TM, Yeo L, Flohr C: Does early life exposure to antibiotics increase the risk of eczema? A systematic review. Br J Dermatol 2013;169:983-991.
  40. Bjorksten B, Naaber P, Sepp E, Mikelsaar M: The intestinal microflora in allergic Estonian and Swedish 2-year-old children. Clin Exp Allergy 1999;29:342-346.
  41. Bjorksten B, Sepp E, Julge K, Voor T, Mikelsaar M: Allergy development and the intestinal microflora during the first year of life. J Allergy Clin Immunol 2001;108:516-520.
  42. Kalliomaki M, Kirjavainen P, Eerola E, Kero P, Salminen S, Isolauri E: Distinct patterns of neonatal gut microflora in infants in whom atopy was and was not developing. J Allergy Clin Immunol 2001;107:129-134.
  43. Watanabe S, Narisawa Y, Arase S, Okamatsu H, Ikenaga T, Tajiri Y, Kumemura M: Differences in fecal microflora between patients with atopic dermatitis and healthy control subjects. J Allergy Clin Immunol 2003;111:587-591.
  44. Wang M, Karlsson C, Olsson C, Adlerberth I, Wold AE, Strachan DP, Martricardi PM, Aberg N, Perkin MR, Tripodi S, Coates AR, Hesselmar B, Saalman R, Molin G, Ahrne S: Reduced diversity in the early fecal microbiota of infants with atopic eczema. J Allergy Clin Immunol 2008;121:129-134.
  45. Naik S, Bouladoux N, Wilhelm C, Molloy MJ, Salcedo R, Kastenmuller W, Deming C, Quinones M, Koo L, Conlan S, Spencer S, Hall JA, Dzutsev A, Kong H, Campbell DJ, Trinchieri G, Segre JA, Belkaid Y: Compartmentalized control of skin immunity by resident commensals. Science 2012;337:1115-1119.
  46. Flohr C, Mann J: New approaches to the prevention of childhood atopic dermatitis. Allergy 2014;69:56-61.
  47. Flohr C: Recent perspectives on the global epidemiology of childhood eczema. Allergol Immunopathol (Madr) 2011;39:174-182.
  48. Flohr C, Nagel G, Weinmayr G, Kleiner A, Strachan DP, Williams HC: Lack of evidence for a protective effect of prolonged breastfeeding on childhood eczema: lessons from the International Study of Asthma and Allergies in Childhood (ISAAC) Phase Two. Br J Dermatol 2011;165:1280-1289.
  49. Filipiak B, Zutavern A, Koletzko S, von Berg A, Brockow I, Grubl A, Berdel D, Reinhardt D, Bauer CP, Wichmann HE, Heinrich J: Solid food introduction in relation to eczema: results from a four-year prospective birth cohort study. J Pediatr 2007;151:352-358.
  50. Roduit C, Frei R, Loss G, Buchele G, Weber J, Depner M, Loeliger S, Dalphin ML, Roponen M, Hyvarinen A, Riedler J, Dalphin JC, Pekkanen J, von Mutius E, Braun-Fahrlander C, Lauener R: Development of atopic dermatitis according to age of onset and association with early-life exposures. J Allergy Clin Immunol 2012;130:130-136.
  51. Sariachvili M, Droste J, Dom S, Wieringa M, Hagendorens M, Stevens W, van SM, Desager K, Weyler J: Early exposure to solid foods and the development of eczema in children up to 4 years of age. Pediatr Allergy Immunol 2010;21:74-81.
  52. Snijders BE, Thijs C, van RR, van den Brandt PA: Age at first introduction of cow milk products and other food products in relation to infant atopic manifestations in the first 2 years of life: the KOALA Birth Cohort Study. Pediatrics 2008;122:e115-e122.
  53. Zutavern A, Brockow I, Schaaf B, von Berg A, Diez U, Borte M, Kraemer U, Herbarth O, Behrendt H, Wichmann HE, Heinrich J: Timing of solid food introduction in relation to eczema, asthma, allergic rhinitis, and food and inhalant sensitization at the age of 6 years: results from the prospective birth cohort study LISA. Pediatrics 2008;121:e44-e52.
  54. Alexander DD, Cabana MD: Partially hydrolyzed 100% whey protein infant formula and reduced risk of atopic dermatitis: a meta-analysis. J Pediatr Gastroenterol Nutr 2010;50:422-430.
    External Resources
  55. Szajewska H, Horvath A: Meta-analysis of the evidence for a partially hydrolyzed 100% whey formula for the prevention of allergic diseases. Curr Med Res Opin 2010;26:423-437.
  56. von Berg A, Koletzko S, Grubl A, Filipiak-Pittroff B, Wichmann HE, Bauer CP, Reinhardt D, Berdel D: The effect of hydrolyzed cow's milk formula for allergy prevention in the first year of life: the German Infant Nutritional Intervention Study, a randomized double-blind trial. J Allergy Clin Immunol 2003;111:533-540.
  57. von Berg A, Filipiak-Pittroff B, Kramer U, Link E, Bollrath C, Brockow I, Koletzko S, Grubl A, Heinrich J, Wichmann HE, Bauer CP, Reinhardt D, Berdel D: Preventive effect of hydrolyzed infant formulas persists until age 6 years: long-term results from the German Infant Nutritional Intervention Study (GINI). J Allergy Clin Immunol 2008;121:1442-1447.
  58. von Berg A, Filipiak-Pittroff B, Kramer U, Hoffmann B, Link E, Beckmann C, Hoffmann U, Reinhardt D, Grubl A, Heinrich J, Wichmann HE, Bauer CP, Koletzko S, Berdel D: Allergies in high-risk schoolchildren after early intervention with cow's milk protein hydrolysates: 10-year results from the German Infant Nutritional Intervention (GINI) study. J Allergy Clin Immunol 2013;131:1565-1573.
  59. Pelucchi C, Chatenoud L, Turati F, Galeone C, Moja L, Bach JF, La Vecchia C: Probiotics supplementation during pregnancy or infancy for the prevention of atopic dermatitis: a meta-analysis. Epidemiology 2012;23:402-414.
  60. Osborn DA, Sinn JK: Prebiotics in infants for prevention of allergy. Cochrane Database Syst Rev 2013;3:CD006474.
  61. Fiocchi A, Burks W, Bahna SL, Bielory L, Boyle RJ, Cocco R, Dreborg S, Goodman R, Kuitunen M, Haahtela T, Heine RG, Lack G, Osborn DA, Sampson H, Tannock GW, Lee BW: Clinical Use of Probiotics in Pediatric Allergy (CUPPA): a World Allergy Organization position paper. World Allergy Organ J 2012;5:148-167.
  62. Bath-Hextall FJ, Jenkinson C, Humphreys R, Williams HC: Dietary supplements for established atopic eczema. Cochrane Database Syst Rev 2012;2:CD005205.
  63. Romieu I, Torrent M, Garcia-Esteban R, Ferrer C, Ribas-Fito N, Anto JM, Sunyer J: Maternal fish intake during pregnancy and atopy and asthma in infancy. Clin Exp Allergy 2007;37:518-525.
  64. Alm B, Aberg N, Erdes L, Mollborg P, Pettersson R, Norvenius SG, Goksor E, Wennergren G: Early introduction of fish decreases the risk of eczema in infants. Arch Dis Child 2009;94:11-15.
  65. Oien T, Storro O, Johnsen R: Do early intake of fish and fish oil protect against eczema and doctor-diagnosed asthma at 2 years of age? A cohort study. J Epidemiol Community Health 2010;64:124-129.

Author Contacts

Sophie Nutten, PhD

Nutrition and Health Department

Nestlé Research Center

PO Box 44, CH-1000 Lausanne 26 (Switzerland)

E-Mail sophie.nutten@rdls.nestle.com


Article / Publication Details

First-Page Preview
Abstract of Atopic Dermatitis

Published online: April 24, 2015
Issue release date: April 2015

Number of Print Pages: 9
Number of Figures: 3
Number of Tables: 2

ISSN: 0250-6807 (Print)
eISSN: 1421-9697 (Online)

For additional information: https://www.karger.com/ANM


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Asher MI, Montefort S, Bjorksten B, Lai CK, Strachan DP, Weiland SK, Williams H: Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. Lancet 2006;368:733-743.
  2. Barnetson RS, Rogers M: Childhood atopic eczema. BMJ 2002;324:1376-1379.
  3. Dharmage SC, Lowe AJ, Matheson MC, Burgess JA, Allen KJ, Abramson MJ: Atopic dermatitis and the atopic march revisited. Allergy 2014;69:17-27.
  4. Shaker M: New insights into the allergic march. Curr Opin Pediatr 2014;26:516-520.
  5. Spergel JM: From atopic dermatitis to asthma: the atopic march. Ann Allergy Asthma Immunol 2010;105:99-106.
  6. Kemp AS: Cost of illness of atopic dermatitis in children: a societal perspective. Pharmacoeconomics 2003;21:105-113.
  7. Mancini AJ, Kaulback K, Chamlin SL: The socioeconomic impact of atopic dermatitis in the United States: a systematic review. Pediatr Dermatol 2008;25:1-6.
  8. Verboom P, Hakkaart-Van L, Sturkenboom M, De Zeeuw R, Menke H, Rutten F: The cost of atopic dermatitis in the Netherlands: an international comparison. Br J Dermatol 2002;147:716-724.
  9. Arnold RJ, Donnelly A, Altieri L, Wong KS, Sung J: Assessment of outcomes and parental effect on quality-of-life endpoints in the management of atopic dermatitis. Manag Care Interface 2007;20:18-23.
    External Resources
  10. Carroll CL, Balkrishnan R, Feldman SR, Fleischer AB Jr, Manuel JC: The burden of atopic dermatitis: impact on the patient, family, and society. Pediatr Dermatol 2005;22:192-199.
  11. Lewis-Jones S: Quality of life and childhood atopic dermatitis: the misery of living with childhood eczema. Int J Clin Pract 2006;60:984-992.
  12. Weisshaar E, Diepgen TL, Bruckner T, Fartasch M, Kupfer J, Lob-Corzilius T, Ring J, Scheewe S, Scheidt R, Schmid-Ott G, Schnopp C, Staab D, Szcepanski R, Werfel T, Wittenmeier M, Wahn U, Gieler U: Itch intensity evaluated in the German Atopic Dermatitis Intervention Study (GADIS): correlations with quality of life, coping behaviour and SCORAD severity in 823 children. Acta Derm Venereol 2008;88:234-239.
    External Resources
  13. Odhiambo JA, Williams HC, Clayton TO, Robertson CF, Asher MI: Global variations in prevalence of eczema symptoms in children from ISAAC Phase Three. J Allergy Clin Immunol 2009;124:1251-1258.
  14. Mallol J, Crane J, von Mutius E, Odhiambo J, Keil U, Stewart A; ISAAC Phase Three Study Group: The International Study of Asthma and Allergies in Childhood (ISAAC) Phase Three: a global synthesis. Allergol Immunopathol (Madr) 2013;41:73-85.
  15. Williams H, Stewart A, von Mutius E, Cookson W, Anderson HR; International Study of Asthma and Allergies in Childhood (ISAAC) Phase One and Three Study Groups: Is eczema really on the increase worldwide? J Allergy Clin Immunol 2008;121:947-954.
  16. Fiset PO, Leung DY, Hamid Q: Immunopathology of atopic dermatitis. J Allergy Clin Immunol 2006;118:287-290.
  17. McGirt LY, Beck LA: Innate immune defects in atopic dermatitis. J Allergy Clin Immunol 2006;118:202-208.
  18. Ong PY, Ohtake T, Brandt C, Strickland I, Boguniewicz M, Ganz T, Gallo RL, Leung DY: Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med 2002;347:1151-1160.
  19. Cardona ID, Cho SH, Leung DY: Role of bacterial superantigens in atopic dermatitis: implications for future therapeutic strategies. Am J Clin Dermatol 2006;7:273-279.
  20. Eigenmann PA, Sicherer SH, Borkowski TA, Cohen BA, Sampson HA: Prevalence of IgE-mediated food allergy among children with atopic dermatitis. Pediatrics 1998;101:E8.
  21. Suh KY: Food allergy and atopic dermatitis: separating fact from fiction. Semin Cutan Med Surg 2010;29:72-78.
    External Resources
  22. Schultz Larsen FV, Holm NV: Atopic dermatitis in a population based twin series. Concordance rates and heritability estimation. Acta Derm Venereol Suppl (Stockh) 1985;114:159.
    External Resources
  23. Palmer CN, Irvine AD, Terron-Kwiatkowski A, Zhao Y, Liao H, Lee SP, Goudie DR, Sandilands A, Campbell LE, Smith FJ, O'Regan GM, Watson RM, Cecil JE, Bale SJ, Compton JG, DiGiovanna JJ, Fleckman P, Lewis-Jones S, Arseculeratne G, Sergeant A, Munro CS, El Houate B, McElreavey K, Halkjaer LB, Bisgaard H, Mukhopadhyay S, McLean WH: Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet 2006;38:441-446.
  24. Barnes KC: An update on the genetics of atopic dermatitis: scratching the surface in 2009. J Allergy Clin Immunol 2010;125:16-29.
  25. Moffatt MF: SPINK5: a gene for atopic dermatitis and asthma. Clin Exp Allergy 2004;34:325-327.
  26. Cork MJ, Robinson DA, Vasilopoulos Y, Ferguson A, Moustafa M, MacGowan A, Duff GW, Ward SJ, Tazi-Ahnini R: New perspectives on epidermal barrier dysfunction in atopic dermatitis: gene-environment interactions. J Allergy Clin Immunol 2006;118:3-21.
  27. Brown SJ, Asai Y, Cordell HJ, Campbell LE, Zhao Y, Liao H, Northstone K, Henderson J, Alizadehfar R, Ben-Shoshan M, Morgan K, Roberts G, Masthoff LJ, Pasmans SG, van den Akker PC, Wijmenga C, Hourihane JO, Palmer CN, Lack G, Clarke A, Hull PR, Irvine AD, McLean WH: Loss-of-function variants in the filaggrin gene are a significant risk factor for peanut allergy. J Allergy Clin Immunol 2011;127:661-667.
  28. Flohr C, Pascoe D, Williams HC: Atopic dermatitis and the ‘hygiene hypothesis': too clean to be true? Br J Dermatol 2005;152:202-216.
  29. Flohr C, Yeo L: Atopic dermatitis and the hygiene hypothesis revisited. Curr Probl Dermatol 2011;41:1-34.
  30. Braback L, Hjern A, Rasmussen F: Trends in asthma, allergic rhinitis and eczema among Swedish conscripts from farming and non-farming environments. A nationwide study over three decades. Clin Exp Allergy 2004;34:38-43.
  31. Braun-Fahrländer C, Gassner M, Grize L, Neu U, Sennhauser FH, Varonier HS, Vuille JC, Wüthrich B: Prevalence of hay fever and allergic sensitization in farmer's children and their peers living in the same rural community. SCARPOL team. Swiss Study on Childhood Allergy and Respiratory Symptoms with Respect to Air Pollution. Clin Exp Allergy 1999;29:28-34.
  32. Douwes J, Cheng S, Travier N, Cohet C, Niesink A, McKenzie J, Cunningham C, Le Gros G, von Mutius E, Pearce N: Farm exposure in utero may protect against asthma, hay fever and eczema. Eur Respir J 2008;32:603-611.
  33. Kilpelainen M, Terho EO, Helenius H, Koskenvuo M: Farm environment in childhood prevents the development of allergies. Clin Exp Allergy 2000;30:201-208.
  34. Riedler J, Eder W, Oberfeld G, Schreuer M: Austrian children living on a farm have less hay fever, asthma and allergic sensitization. Clin Exp Allergy 2000;30:194-200.
  35. von Mutius E: Maternal farm exposure/ingestion of unpasteurized cow's milk and allergic disease. Curr Opin Gastroenterol 2012;28:570-576.
  36. Langan SM, Flohr C, Williams HC: The role of furry pets in eczema: a systematic review. Arch Dermatol 2007;143:1570-1577.
  37. Pelucchi C, Galeone C, Bach JF, La Vecchia C, Chatenoud L: Pet exposure and risk of atopic dermatitis at the pediatric age: a meta-analysis of birth cohort studies. J Allergy Clin Immunol 2013;132:616-622.
  38. Dom S, Droste JH, Sariachvili MA, Hagendorens MM, Oostveen E, Bridts CH, Stevens WJ, Wieringa MH, Weyler JJ: Pre- and post-natal exposure to antibiotics and the development of eczema, recurrent wheezing and atopic sensitization in children up to the age of 4 years. Clin Exp Allergy 2010;40:1378-1387.
  39. Tsakok T, McKeever TM, Yeo L, Flohr C: Does early life exposure to antibiotics increase the risk of eczema? A systematic review. Br J Dermatol 2013;169:983-991.
  40. Bjorksten B, Naaber P, Sepp E, Mikelsaar M: The intestinal microflora in allergic Estonian and Swedish 2-year-old children. Clin Exp Allergy 1999;29:342-346.
  41. Bjorksten B, Sepp E, Julge K, Voor T, Mikelsaar M: Allergy development and the intestinal microflora during the first year of life. J Allergy Clin Immunol 2001;108:516-520.
  42. Kalliomaki M, Kirjavainen P, Eerola E, Kero P, Salminen S, Isolauri E: Distinct patterns of neonatal gut microflora in infants in whom atopy was and was not developing. J Allergy Clin Immunol 2001;107:129-134.
  43. Watanabe S, Narisawa Y, Arase S, Okamatsu H, Ikenaga T, Tajiri Y, Kumemura M: Differences in fecal microflora between patients with atopic dermatitis and healthy control subjects. J Allergy Clin Immunol 2003;111:587-591.
  44. Wang M, Karlsson C, Olsson C, Adlerberth I, Wold AE, Strachan DP, Martricardi PM, Aberg N, Perkin MR, Tripodi S, Coates AR, Hesselmar B, Saalman R, Molin G, Ahrne S: Reduced diversity in the early fecal microbiota of infants with atopic eczema. J Allergy Clin Immunol 2008;121:129-134.
  45. Naik S, Bouladoux N, Wilhelm C, Molloy MJ, Salcedo R, Kastenmuller W, Deming C, Quinones M, Koo L, Conlan S, Spencer S, Hall JA, Dzutsev A, Kong H, Campbell DJ, Trinchieri G, Segre JA, Belkaid Y: Compartmentalized control of skin immunity by resident commensals. Science 2012;337:1115-1119.
  46. Flohr C, Mann J: New approaches to the prevention of childhood atopic dermatitis. Allergy 2014;69:56-61.
  47. Flohr C: Recent perspectives on the global epidemiology of childhood eczema. Allergol Immunopathol (Madr) 2011;39:174-182.
  48. Flohr C, Nagel G, Weinmayr G, Kleiner A, Strachan DP, Williams HC: Lack of evidence for a protective effect of prolonged breastfeeding on childhood eczema: lessons from the International Study of Asthma and Allergies in Childhood (ISAAC) Phase Two. Br J Dermatol 2011;165:1280-1289.
  49. Filipiak B, Zutavern A, Koletzko S, von Berg A, Brockow I, Grubl A, Berdel D, Reinhardt D, Bauer CP, Wichmann HE, Heinrich J: Solid food introduction in relation to eczema: results from a four-year prospective birth cohort study. J Pediatr 2007;151:352-358.
  50. Roduit C, Frei R, Loss G, Buchele G, Weber J, Depner M, Loeliger S, Dalphin ML, Roponen M, Hyvarinen A, Riedler J, Dalphin JC, Pekkanen J, von Mutius E, Braun-Fahrlander C, Lauener R: Development of atopic dermatitis according to age of onset and association with early-life exposures. J Allergy Clin Immunol 2012;130:130-136.
  51. Sariachvili M, Droste J, Dom S, Wieringa M, Hagendorens M, Stevens W, van SM, Desager K, Weyler J: Early exposure to solid foods and the development of eczema in children up to 4 years of age. Pediatr Allergy Immunol 2010;21:74-81.
  52. Snijders BE, Thijs C, van RR, van den Brandt PA: Age at first introduction of cow milk products and other food products in relation to infant atopic manifestations in the first 2 years of life: the KOALA Birth Cohort Study. Pediatrics 2008;122:e115-e122.
  53. Zutavern A, Brockow I, Schaaf B, von Berg A, Diez U, Borte M, Kraemer U, Herbarth O, Behrendt H, Wichmann HE, Heinrich J: Timing of solid food introduction in relation to eczema, asthma, allergic rhinitis, and food and inhalant sensitization at the age of 6 years: results from the prospective birth cohort study LISA. Pediatrics 2008;121:e44-e52.
  54. Alexander DD, Cabana MD: Partially hydrolyzed 100% whey protein infant formula and reduced risk of atopic dermatitis: a meta-analysis. J Pediatr Gastroenterol Nutr 2010;50:422-430.
    External Resources
  55. Szajewska H, Horvath A: Meta-analysis of the evidence for a partially hydrolyzed 100% whey formula for the prevention of allergic diseases. Curr Med Res Opin 2010;26:423-437.
  56. von Berg A, Koletzko S, Grubl A, Filipiak-Pittroff B, Wichmann HE, Bauer CP, Reinhardt D, Berdel D: The effect of hydrolyzed cow's milk formula for allergy prevention in the first year of life: the German Infant Nutritional Intervention Study, a randomized double-blind trial. J Allergy Clin Immunol 2003;111:533-540.
  57. von Berg A, Filipiak-Pittroff B, Kramer U, Link E, Bollrath C, Brockow I, Koletzko S, Grubl A, Heinrich J, Wichmann HE, Bauer CP, Reinhardt D, Berdel D: Preventive effect of hydrolyzed infant formulas persists until age 6 years: long-term results from the German Infant Nutritional Intervention Study (GINI). J Allergy Clin Immunol 2008;121:1442-1447.
  58. von Berg A, Filipiak-Pittroff B, Kramer U, Hoffmann B, Link E, Beckmann C, Hoffmann U, Reinhardt D, Grubl A, Heinrich J, Wichmann HE, Bauer CP, Koletzko S, Berdel D: Allergies in high-risk schoolchildren after early intervention with cow's milk protein hydrolysates: 10-year results from the German Infant Nutritional Intervention (GINI) study. J Allergy Clin Immunol 2013;131:1565-1573.
  59. Pelucchi C, Chatenoud L, Turati F, Galeone C, Moja L, Bach JF, La Vecchia C: Probiotics supplementation during pregnancy or infancy for the prevention of atopic dermatitis: a meta-analysis. Epidemiology 2012;23:402-414.
  60. Osborn DA, Sinn JK: Prebiotics in infants for prevention of allergy. Cochrane Database Syst Rev 2013;3:CD006474.
  61. Fiocchi A, Burks W, Bahna SL, Bielory L, Boyle RJ, Cocco R, Dreborg S, Goodman R, Kuitunen M, Haahtela T, Heine RG, Lack G, Osborn DA, Sampson H, Tannock GW, Lee BW: Clinical Use of Probiotics in Pediatric Allergy (CUPPA): a World Allergy Organization position paper. World Allergy Organ J 2012;5:148-167.
  62. Bath-Hextall FJ, Jenkinson C, Humphreys R, Williams HC: Dietary supplements for established atopic eczema. Cochrane Database Syst Rev 2012;2:CD005205.
  63. Romieu I, Torrent M, Garcia-Esteban R, Ferrer C, Ribas-Fito N, Anto JM, Sunyer J: Maternal fish intake during pregnancy and atopy and asthma in infancy. Clin Exp Allergy 2007;37:518-525.
  64. Alm B, Aberg N, Erdes L, Mollborg P, Pettersson R, Norvenius SG, Goksor E, Wennergren G: Early introduction of fish decreases the risk of eczema in infants. Arch Dis Child 2009;94:11-15.
  65. Oien T, Storro O, Johnsen R: Do early intake of fish and fish oil protect against eczema and doctor-diagnosed asthma at 2 years of age? A cohort study. J Epidemiol Community Health 2010;64:124-129.
ppt logo Download Images (.pptx)


Figures
Thumbnail
Thumbnail
Thumbnail

Tables
Thumbnail
Thumbnail